Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUPPITS-2: Mepolizumab for Asthma Exacerbation Prevention in Urban Children
NCT03292588Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2017
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Mepolizumab with Placebo (2 arms). Primary endpoint: Number of Asthma Exacerbations During the Treatment Period at 12 months. Started Nov 2017; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03292588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292588.